絞り込み

16377

広告

Use of myeloablative Y90-ibritumomab tiuxetan in patients with high-risk CD20+ NHL not eligible for standard ASCT: Five-year results.

著者 Devizzi L , Guidetti A , Carlo-Stella C , Tarella C , Seregni E , Magni M , Di Nicola MA , Schiavello E , Matteucci P , Viviani S , Bombardieri E , Gianni AM
J Clin Oncol.2011 May 20 ; 29(15_suppl):8019.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (15view , 0users)
  • このエントリーをはてなブックマークに追加
8019 Background: ASCT is the procedure of choice in poor risk NHL, however conditioning regimens is a challenging procedures because safely delivered only in younger and clinically fit patients, thus new approaches are suggested to enhance its applicability. To extend the probability of cure to pts not eligible to standard ASCT from 12/2003 to 7/2007, 60 high-risk CD20+ NHL pts have been included in a phase II study with myeloablative Y90-Ibritumomab Tiuxetan, supported by ASCT.
PMID: 28023007 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード